Gene therapy approaches for the treatment of Parkinson's disease

Handbook of Clinical Neurology

Volumn 84, Issue , 2007, Pages 291-304

  Dass, Biplob ^a   Kordower, Jeffrey H ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67649415136     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0072-9752(07)84045-0     Document Type: Chapter

References (82)

1. Amgen Press Release 28th June 2004. Amgen's Phase 2 Study of GDNF for Advanced Parkinson's Disease Fails to Meet Primary Endpoint; Six Months of Treatment Showed Biological Effect But No Clinical Improvement. http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2004&releaseI D=585632
2. Amgen Press Release 11th Feb 2005. Following Complete Review of Phase 2 Trial Data Amgen Confirms Decision to Halt GDNF Study; Comprehensive Review of Scientific Findings, Patient Safety, Drove Decision. http://wwwext.amgen.com/media/media_pr_detail.jsp?year=2005&releaseI D=673490
3. Avigen Press Release 18th July 2005. Avigen Announces Encouraging Early Data from Parkinson's Disease Clinical Trial. Evidence for First Successful Gene Transfer of AADC Gene in Humans. http://www.avigen.com/non_financial_release/2005/2005_Avigen_EarlyData_P DClinicalTrial_071805.htm
4. Azzouz M., Martin-Rendon E., Barber R.D., et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 22 23 (2002) 10302-10312
5. Bankiewicz K.S., Eberling J.L., Kohutnicka M., et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164 1 (2000) 2-14
6. Bankiewicz K.S., Daadi M., Pivirotto P., et al. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol 197 2 (2006) 363-372 [Epub 2005 Dec 9]
7. Bartus R.T., Herzog C.D., Cunningham J.J., et al. Biological activity of CERE-120, an AAV2 vector encoding human neurturin, in the rat 6-hydroxydopamine model of nigrostriatal degeneration and in the young intact and aged rat. J Neurosci (2005) #545.1
8. Bilang-Bleuel A., Revah F., Colin P., et al. Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 94 16 (1997) 8818-8823
9. Brundin P., Nilsson O.G., Strecker R.E., et al. Behavioural effects of human fetal dopamine neurons grafted in a rat model of Parkinson's disease. Exp Brain Res 65 1 (1986) 235-240
10. Choi-Lundberg D.L., Lin Q., Chang Y.N., et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275 5301 (1997) 838-841
11. Choi-Lundberg D.L., Lin Q., Schallert T., et al. Behavioral and cellular protection of rat dopaminergic neurons by an adenoviral vector encoding glial cell line-derived neurotrophic factor. Exp Neurol 154 2 (1998) 261-275
12. Collier T.J., and Sortwell C.E. Therapeutic potential of nerve growth factors in Parkinson's disease. Drugs Aging 14 4 (1999) 261-287 Review
13. Connor B., Kozlowski D.A., Schallert T., et al. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther 6 12 (1999) 1936-1951
14. Curtis L., Lees A.J., Stern G.M., et al. Effect of L-DOPA on course of Parkinson's disease. Lancet 2 8396 (1984) 211-212
15. Date I., Imaoka T., Miyoshi Y., et al. Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. J Neurosurg 84 4 (1996) 685-689
16. Deacon T., Schumacher J., Dinsmore J., et al. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nat Med 3 3 (1997) 350-353
17. Dass B., Iravani M.M., Jackson M.J., et al. Behavioural and immunohistochemical changes following supranigral administration of sonic hedgehog in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Neuroscience 114 1 (2002) 99-109
18. Dass B., Herzog C.D., Gasmi M., et al. Adeno-associated virus mediated gene delivery of neurturin (CERE-120) in non-human primates. J Neurosci (2004) #790.19
19. Dass B., Herzog C.D., Gasmi M., et al. Adeno-associated virus mediated gene delivery of neurturin (CERE-120) prevents MPTP-induced motor disability following injection into the striatum of non-human primates. J Neurosci (2005) #545.6
20. Dass B., Iravani M.M., Huang C., et al. Sonic hedgehog delivered by an adeno-associated virus protects dopaminergic neurones against 6-OHDA toxicity in the rat. J Neural Transm 112 6 (2005) 763-778 [Epub 2004 Dec 10]
21. de la Fuente-Fernandez R., Ruth T.J., Sossi V., et al. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293 5532 (2001) 1164-1166
22. During M.J., Samulski R.J., Elsworth J.D., et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 5 6 (1998) 820-827
23. During M.J., Kaplitt M.G., Stern M.B., et al. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12 12 (2001) 1589-1591
24. Eberhardt O., Coelln R.V., Kugler S., et al. Protection by synergistic effects of adenovirus-mediated X-chromosome-linked inhibitor of apoptosis and glial cell line-derived neurotrophic factor gene transfer in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J Neurosci 20 24 (2000) 9126-9134
25. Ehringer H., and Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramine) im gerhin des menschen und ihr verhalten bei erkrantungen des extrapyramidalen systems. Kiln Wschr 38 (1960) 1236-1239
26. Eslamboli A., Cummings R.M., Ridley R.M., et al. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol 184 1 (2003) 536-548
27. Eslamboli A., Georgievska B., Ridley R.M., et al. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 25 4 (2005) 769-777
28. Figueiras-Mendez R., Marin-Zarza F., Antonio, Molina J., et al. Subthalamic nucleus stimulation improves directly levodopa induced dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 66 4 (1999) 549-550
29. Fjord-Larsen L., Johansen J.L., Kusk P., et al. Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp Neurol 195 1 (2005) 49-60
30. Freed C.R., Greene P.E., Breeze R.E., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 10 (2001) 710-719
31. Gash D.M., Zhang Z., Ovadia A., et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380 6571 (1996) 252-255
32. Georgievska B., Kirik D., Rosenblad C., et al. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 13 1 (2002) 75-82
33. Georgievska B., Kirik D., and Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 177 2 (2002) 461-474
34. Georgievska B., Kirik D., and Bjorklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci 24 29 (2004) 6437-6445
35. Gill S.S., Patel N.K., Hotton G.R., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 5 (2003) 589-595
36. Hacein-Bey-Abina S., von Kalle C., Schmidt M., et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 348 3 (2003) 255-256
37. Herzog C.D., Holden J.E., Bakay R.A., et al. Enhanced 18F-dopa uptake in the striatum of aged rhesus monkeys following striatal delivery of CERE-120, an AAV2 vector encoding human neurturin. J Neurosci (2005) #545.7
38. Hurtado-Lorenzo A., Millan E., Gonzalez-Nicolini V., et al. Differentiation and transcription factor gene therapy in experimental Parkinson's disease: Sonic Hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration. Mol Ther 10 3 (2004) 507-524
39. Kaplitt M.G., Leone P., Samulski R.J., et al. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8 2 (1994) 148-154
40. Kirik D., Rosenblad C., and Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 12 11 (2000) 3871-3882
41. Kirik D., Rosenblad C., Bjorklund A., et al. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 20 12 (2000) 4686-4700
42. Kirik D., Georgievska B., Burger C., et al. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-DOPA using rAAV-mediated gene transfer. Proc Natl Acad Sci USA 99 7 (2002) 4708-4713 [Epub 2002 Mar 26]
43. Klein R.L., Lewis M.H., Muzyczka N., et al. Prevention of 6-hydroxydopamine-induced rotational behavior by BDNF somatic gene transfer. Brain Res 847 2 (1999) 314-320
44. Kojima H., Abiru Y., Sakajiri K., et al. Adenovirus-mediated transduction with human glial cell line-derived neurotrophic factor gene prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopamine depletion in striatum of mouse brain. Biochem Biophys Res Commun 238 2 (1997) 569-573
45. Kordower J.H., Freeman T.B., Snow B.J., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 332 17 (1995) 1118-1124
46. Kordower J.H., Palfi S., Chen E.Y., et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 46 3 (1999) 419-424
47. Kordower J.H., Emborg M.E., Bloch J., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290 5492 (2000) 767-773
48. Kotzbauer P.T., Lampe B.A., Heuckeroth R.O., et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 384 (1996) 467-470
49. Lapchak P.A., Araujo D.M., Hilt D.C., et al. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res 777 1-2 (1997) 153-160
50. Lindvall O., Rehncrona S., Brundin P., et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease. A detailed account of methodology and a 6-month follow-up. Arch Neurol 46 6 (1989) 615-631
51. Lo Bianco C., Deglon N., Pralong W., et al. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. Neurobiol Dis 17 2 (2004) 283-289
52. Luo J., Kaplitt M.G., Fitzsimons H.L., et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298 5592 (2002) 425-429
53. Madrazo I., Drucker-Colin R., Diaz V., et al. Open microsurgical autograft of adrenal medulla to the right caudate nucleus in two patients with intractable Parkinson's disease. N Engl J Med 316 14 (1987) 831-834
54. Mandel R.J., Spratt S.K., Snyder R.O., et al. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci USA 94 25 (1997) 14083-14088
55. Mandel R.J., Rendahl K.G., Spratt S.K., et al. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 18 11 (1998) 4271-4284
56. Marsden C.D. Parkinson's disease. Lancet 335 8695 (1990) 948-952
57. Marsden C.D., and Parkes J.D. Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1 8007 (1977) 345-349
58. Mufson E.J., Kroin J.S., Sendera T.J., et al. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 57 4 (1999) 451-484 Review
59. Muramatsu S., Fujimoto K., Ikeguchi K., et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13 3 (2002) 345-354
60. Nakai H., Montini E., Fuess S., et al. AAV serotype 2 vectors preferentially integrate into active genes in mice. Nat Genet 34 3 (2003) 297-302
61. Natsume A., Mata M., Goss J., et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp Neurol 169 2 (2001) 231-238
62. Neurologix Press Release 25th September 2005. Neurologix Announces PositiveInterim Results of Landmark Gene Therapy Clinical Trial for Patients with Parkinson's Disease. http://phx.corporate-ir.net/phoenix.zhtml?c=106413p =irol-newsArticleID=760701highlight=
63. Nutt J.G., Burchiel K.J., Comella C.L., et al., ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic factor. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60 1 (2003) 69-73
64. Ostenfeld T., Tai Y.T., Martin P., et al. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res 69 6 (2002) 955-965
65. Palfi S., Leventhal L., Chu Y., et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 22 12 (2002) 4942-4954
66. Park S., Kim E.Y., Ghil G.S., et al. Genetically modified human embryonic stem cells relieve symptomatic motor behavior in a rat model of Parkinson's disease. Neurosci Lett 353 2 (2003) 91-94
67. Pearce R.K.B., Collins P., Jenner P., et al. Intraventricular infusion of basic fibroblast growth factor (bFGF) in the MPTP treated common marmoset. Synapse 23 (1996) 192-200
68. Pearce R.K.B., Costa S., Jenner P., et al. Chronic supranigral infusion of BDNF in normal and MPTP treated common marmosets. J Neural Transm 106 (1999) 663-683
69. Quinn N.P. The clinical application of cell grafting techniques in patients with Parkinson's disease. Prog Brain Res 82 (1990) 619-625
70. Raper S.E., Chirmule N., Lee F.S., et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 80 1-2 (2003) 148-158
71. Sanchez-Pernaute R., Harvey-White J., Cunningham J., et al. Functional effect of adeno-associated virus mediated gene transfer of aromatic L-amino acid decarboxylase into the striatum of 6-OHDA-lesioned rats. Mol Ther 4 4 (2001) 324-330
72. Schumacher J.M., Ellias S.A., Palmer E.P., et al. Transplantation of embryonic porcine mesencephalic tissue in patients with PD. Neurology 54 5 (2000) 1042-1050
73. Shen Y., Muramatsu S.I., Ikeguchi K., et al. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 11 11 (2000) 1509-1519
74. Slevin J.T., Gerhardt G.A., Smith C.D., et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102 2 (2005) 216-222
75. Smith A.D., Kozlowski D.A., Bohn M.C., et al. Effect of AdGDNF on dopaminergic neurotransmission in the striatum of 6-OHDA-treated rats. Exp Neurol 193 2 (2005) 420-426
76. Steece-Collier K., Collier T.J., Danielson P.D., et al. Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats. Mov Disord 18 (2003) 1442-1454
77. Svendsen C.N., Clarke D.J., Rosser A.E., et al. Survival and differentiation of rat and human epidermal growth factor-responsive precursor cells following grafting into the lesioned adult central nervous system. Exp Neurol 137 2 (1996) 376-388
78. Tomac A., Widenfalk J., Lin L.F., et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc Natl Acad Sci USA 92 18 (1995) 8274-8278
79. Wang L., Muramatsu S., Lu Y., et al. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Ther 9 6 (2002) 381-389
80. Wenning G.K., Odin P., Morrish P., et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 42 1 (1997) 95-107
81. Wolff J.A., Fisher L.J., Xu L., et al. Grafting fibroblasts genetically modified to produce L-DOPA in a rat model of Parkinson disease. Proc Natl Acad Sci USA 86 22 (1989) 9011-9014
82. Yamada M., Oligino T., Mata M., et al. Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine-induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 96 7 (1999) 4078-4083